Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 50 of 74 publications.
Skip to main content
Davis AE, Blake M, Lehoucq M, Brogan AJ, McDade C, Carlson KB, Lopman B, Buck PO. Estimates of the public health impact of norovirus vaccination for older adults in the United States. Poster presented at the ISPOR 2025; May 16, 2025. Montréal, Canada.
Earnshaw S, Brogan AJ, Brodtkorb TH, Davis AE. Budget impact analysis II: applications and design issues - virtual. Presented at the 2024 Virtual ISPOR Short Course Program; December 4, 2024. Previously presented at the 2015 ISPOR 20th Annual International Meeting.
Neches V, Campbell K, Coll P, Moreno Guillen S, Martinez-Sesmero JM, Lopez Segui F, O'Brien P, Davis A, Anderson SJ, Schroeder M, Vallejo-Aparicio LA. Cost-effectiveness of cabotegravir long-acting for pre-exposure prophylaxis versus current use of daily oral tenofovir disoproxil fumarate/emtricitabine or no prep to prevent HIV-1 in individuals at high risk in Spain. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S121. doi: 10.1016/j.jval.2024.10.620
Adelakun A, Dolph M, Matthews E, Oglebsy A, Campbell K, Davis A, Xu J, Hardy I, Danchenko N, Anderson SJ. Cost-effectiveness and public-health impact of cabotegravir long-acting injectable for HIV pre-exposure prophylaxis in Canada. Poster presented at the HIV Drug Therapy Glasgow 2024; November 10, 2024. Glasgow, Scotland. [abstract] J Int AIDS Soc. 2024 Nov; 27:234-5.
O'Brien P, Campbell K, Anderson SJ, Cornic L, Davis A, Schroeder M. Cost-effectiveness of every two month Cabotegravir Long-Acting (CAB-LA) for Pre-exposure Prophylaxis (PrEP) compared with daily oral Tenofovir Disoproxil Fumarate (TDF)/ emtricitabine (FTC) as PrEP to prevent HIV-1 UK. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S109. doi: 10.1016/j.jval.2024.03.580
Brogan AJ, Davis AE, Mellott CE, Fraysse J, Metzner AA, Oglesby AK. Cost-effectiveness of cabotegravir long-acting for HIV pre-exposure prophylaxis in the United States. Pharmacoeconomics. 2024 Apr;42(4):447-61. doi: 10.1007/s40273-023-01342-y
Brodtkorb T-H, Brogan A, Davis A, Earnshaw S. Budget impact analysis II: applications and design issues. Presented at the ISPOR Europe 2023; November 12, 2023. Copenhagen, Denmark. Previously presented at the 2022 Virtual ISPOR Short Course Program.
Davis A, Cook C, Graham J, Diaz-Decaro J, Myers E, Buck P. Modelling the public health impact of routine pediatric vaccination for the prevention of cytomegalovirus and congenital cytomegalovirus at the population-level. Poster presented at the 41st Annual Meeting of ESPID 2023; May 8, 2023. Lisbon, Portugal.
Bisanzio D, Davis AE, Talbird SE, Van Effelterre T, Metz L, Gaudig M, Mathieu VO, Brogan AJ. Targeted preventive vaccination campaigns to reduce Ebola outbreaks: an individual-based modeling study. Vaccine. 2022 Dec 14;S0264-410X(22):01449-9. doi: 10.1016/j.vaccine.2022.11.036
Earnshaw S, Brogan A, Brodtkorb TH, Davis AE. Budget impact analysis II: applications and design issues. Presented at the 2022 Virtual ISPOR Short Course Program; September 21, 2022. Previously presented at the 2021 Virtual ISPOR Short Course Program.
Oglesby A, Davis AE, Mellott CE, Fraysse J, Swygard H, Brogan A. Estimating the number of individuals needed to treat with different pre-exposure Prophylaxis options to avoid 1 new HIV-1 infection in the United States. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).
Davis A, Brogan A, Mellott CE, Fraysse J, Oglesby A. Cost-effectiveness of every two month Cabotegravir long-acting (CAB-LA) compared with daily oral Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) for pre-exposure Prophylaxis (PrEP) to prevent HIV-1 infection in the United States. Presented at the ISPOR 2022 Conference; May 10, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).
Davis AE, Earnshaw SR, Mullins CD. Budget impact analysis 1: a 6-step approach. Presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. Previously presented at the ISPOR 18th Annual European Congress.
Earnshaw S, Brogan AJ, Brodtkorb T-H, Davis AE. Budget impact analysis II: applications and design issues. Presented at the 2021 Virtual ISPOR Short Course Program; December 6, 2021. Previously presented at the ISPOR 20th Annual International Meeting.
Bisanzio D, Davis AE, Talbird SE, Van Effelterre T, Metz L, Mathieu VO, Brogan AJ. Individual-based modeling of Ebola outbreaks in the DRC to assess the impact of preventive vaccination strategies. Poster presented at the 8th International Conference on Infectious Disease Dynamics; November 30, 2021. Bologna, Italy.
Davis A, Jiang J, Talbird S, Turpin RS, Mellott CE, Boules M, Wojtowicz AM, Fan T. Pharmacological costs for the treatment of eosinophilic esophagitis in the USA. Poster presented at the 2021 Virtual Digestive Disease Week (DDW) Conference; May 21, 2021. Previously presented at the 2021 AMCP Conference.
Brogan AJ, Talbird SE, Davis AE, La EM, Kumar PN. The cost-effectiveness and budget impact of ibalizumab-uiyk for adults with multidrug-resistant HIV-1 infection in the United States. Pharmacoeconomics. 2021 Apr;39(4):421-32. doi: 10.1007/s40273-020-00992-6
Davis AE, Jiang J, Talbird SE, Turpin R, Mellott CE, Boules M, Wojtowicz AM, Fan T. Pharmacological costs for the treatment of eosinophilic esophagitis in the USA. Poster presented at the 2021 Virtual AMCP; April 2021.
La EM, Talbird SE, Brogan AJ, Davis AE. Budget-impact analysis of ibalizumab in the treatment of US Medicare beneficiaries with multidrug-resistant HIV-1 infection. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S174. doi: 10.1016/j.jval.2020.04.371
Brogan AJ, Talbird SE, Davis AE, Wild L, Flanagan D. Is increased screening and early antiretroviral treatment for HIV-1 worth the investment? An analysis of the public health and economic impact of improvement in the UK. HIV Med. 2019 Nov;20(10):668-80. doi: 10.1111/hiv.12788
Davis A, Brogan AJ, Talbird S, Wild L, Flanagan D. The public health and economic impact of increased screening and immediate initiation of antiretroviral treatment for HIV-1 in the UK. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.
Earnshaw SR, Brogan AJ, Davis AE. Budget impact analysis II: applications & design issues. Presented at the 2018 ISPOR 21st Annual European Congress; November 11, 2018. Barcelona, Spain. Previously presented at the ISPOR 20th Annual International Meeting.
Brogan AJ, Davis AE, Goodwin B. Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States. PLoS One. 2018 Aug 30;13(8):e0203293. doi: 10.1371/journal.pone.0203293
Brogan AJ, Talbird SE, Davis AE, La EM, Miao Z, Lewis S. Long-term health benefit of ibalizumab in the treatment of adults with multidrug-resistant HIV-1 infection. Presented at the 2018 ISPOR 23rd Annual International Meeting; May 23, 2018. Baltimore, MD.
Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Brogan AJ, Talbird SE, Davis AE, Thommes EW, Meier G. Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: a dynamic transmission modeling approach. Hum Vaccin Immunother. 2017 Mar 4;13(3):533-42. doi: 10.1080/21645515.2016.1242541
Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Cost analysis of Raltegravir versus Atazanavir/r or Darunavir/r for treatment-naive adults with HIV-1 infection in Spain. Poster presented at the 2016 ISPOR 19th Annual European Congress; October 31, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A410.
Davis AE, Brogan AJ, Goodwin BB. Cost analysis of raltegravir versus atazanavir/r or darunavir/r for treatment-naive adults with HIV-1 infection in the United States. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A214-5.
Davis AE, Mehrotra S, Friedewald JJ, Daskin MS, Skaro AI, Abecassis MM, Ladner DP. Improving geographic equity in kidney transplantation using alternative kidney sharing and optimization modeling. Med Decis Making. 2015 Aug;35(6):797-807. doi: 10.1177/0272989X14557696
Davis AE, Mehrota S, Ladner DP, Kilambi V, Friedewald JJ. Changes in geographic disparity in kidney transplantation since the final rule. Transplantation. 2014 Nov 15;98(9):931-6. doi: 10.1097/TP.0000000000000446
McElroy LM, Daud A, Davis AE, Lapin B, Baker T, Abecassis MM, Levitsky J, Holl JL, Ladner DP. A meta-analysis of complications following deceased donor liver transplant. Am J Surg. 2014 Oct;208(4):605-18. doi: 10.1016/j.amjsurg.2014.06.006
Davis AE, Mehrotra S, Kilambi V, Kang J, McElroy L, Lapin B, Holl J, Abecassis M, Friedewald JJ, Ladner DP. The effects of the statewide sharing variance on geographic disparity in kidney transplantation in the United States. Clin J Am Soc Nephrol. 2014 Aug 7;9(8):1149-60.
Davis AE, Mehrotra S, McElroy LM, Friedewald JJ, Skaro AI, Lapin B, Kang R, Holl JL, Abecassis MM, Ladner DP. The extent and predictors of waiting time geographic disparity in kidney transplantation in the United States. Transplantation. 2014 May 27;97(10):1049-57. doi: 10.1097/01.tp.0000438623.89310.dc
Davis A, Mehrotra S, Holl J, Daskin MS. Nurse staffing under demand uncertainty to reduce costs and enhance patient safety. Asia Pac J Oper. 2014 Feb;31(1):1-19. doi: 10.1142/S0217595914500055
Davis AE, Mehrotra S, Friedewald J, Ladner D. Characteristics of a simulation model of the national kidney transplantation system. Poster presented at the 2013 Winter Simulation Conference: Simulation: Making Decisions in a Complex World; December 2013. [abstract] Ieee/Acm Trans Comput Biol Bioinform. 2013 Dec; p.2320-9.
Davis AE, Mehrotra S, Friedewald J, Ladner D. Predicting long run geographic disparities in kidney transplantation via fluid approximations. Poster presented at the Institute for Operations Research and Management Science (INFORMS) Healthcare Conference; June 2013.
Davis AE, Mehrotra S, McElroy L. Predictors of kidney transplantation waiting time inequity across the United States. Poster presented at the American Transplant Congress; May 2013. Previously presented at the 13th Annual State of the Art Winter Symposium of the American Society of Transplant Surgeons.
Davis AE, Mehrotra S, McElroy L. Implications of statewide sharing on geographic disparity in kidney transplantation in the US. Poster presented at the American Transplant Congress; May 2013.
Davis AE, Mehrotra S, McElroy L. Predictors of kidney transplantation waiting time inequity across the United States. Poster presented at the 13th Annual State of the Art Winter Symposium of the American Society of Transplant Surgeons; February 2013.
Davis AE, McElroy L, Friedewald J. Examining the influence of biopsy on organ utilization in a single OPO. Poster presented at the 13th Annual State of the Art Winter Symposium of the American Society of Transplant Surgeons; February 2013.